| abstract |
The present invention is a method for the treatment of reducing the level of LDL-cholesterol in a subject infected with hepatitis C virus (HCV) or at high risk of suffering from HCV, which is specific for human PCSK9 protein Administering a therapeutically effective amount of an antagonist antibody that binds to a subject in need thereof. The subject treatments include cholesterol and lipoproteins, including hypercholesterolemia, dyslipidemia, hyperlipidemia, atherosclerosis, acute coronary syndrome, and more generally cardiovascular disease (CVD) It can be used in the prevention and / or treatment of metabolic disorders. [Figure 1] |